Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02123758 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
57
Enrollment target
7
Study locations

NCT02123758: Active Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals.

NCT02123758 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Prostatic Neoplasms that is active but no longer recruiting, run by Aragon Pharmaceuticals. The registered enrollment target is 57 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (71% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02123758, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Prostatic Neoplasms, is active but no longer recruiting, sponsored by Aragon Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
57 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Primary Outcome

The AUC (0-24) is area under the plasma concentration-time curve from time zero to time 24 hours.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer Prostatic Neoplasms

Interventions

  • DRUG Prednisone
  • DRUG Abiraterone Acetate
  • DRUG JNJ-56021927

Study Locations (7)

California

  • - Los Angeles
  • - San Francisco

Other

  • - Rotterdam
  • - Sutton

Texas

  • - Houston

British Columbia

  • - Vancouver

Quebec

  • - Montreal

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2014-07-09
Est. Completion 2027-12-31
Phase Phase 1
Aragon Pharmaceuticals

12 total trials

What the registry record for NCT02123758 still lists

NCT02123758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (71% lower).

The record links to 2 conditions, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Prednisone is the first listed.

NCT02123758 lists 7 locations in 5 states (California, Other, Texas).

Frequently Asked Questions

What is clinical trial NCT02123758 about?

NCT02123758 is a clinical study titled "A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potential...

What is the current status of trial NCT02123758?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2014-07-09. Estimated completion is 2027-12-31.

What conditions does trial NCT02123758 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms.

What interventions are being tested in trial NCT02123758?

The interventions under investigation include: Prednisone (DRUG), Abiraterone Acetate (DRUG), JNJ-56021927 (DRUG).

Who is sponsoring clinical trial NCT02123758?

This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02123758 being conducted?

This trial has 7 study locations across California, Texas, British Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02123758's enrollment target sits among peer trials

57 41st of 69 higher than 29 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02123758, the US trial registry maintained by the National Library of Medicine. NCT02123758 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.